14 July 2008 - Actelion Ltd (SWX: ATLN) and GlaxoSmithKline (LSE and NYSE: GSK) announced that they have entered into an exclusive worldwide collaboration (excluding Japan) for Actelion's almorexant, an orexin receptor antagonist in phase III development with first-in-class potential as a treatment for primary insomnia. Under the terms of the agreement, GSK will receive exclusive worldwide rights to co-develop and co-commercialise almorexant. Actelion will continue to lead the ongoing development programme and potential registration for almorexant in the first indication, primary insomnia, with GSK contributing 40 per cent of the costs.
Almorexant will also be studied in other orexin-related disorders and all costs related to these programmes will be shared equally... Actelion's Press Release - GSK's Press Release -
Almorexant will also be studied in other orexin-related disorders and all costs related to these programmes will be shared equally... Actelion's Press Release - GSK's Press Release - 
